Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (3384)	6/29/1999 5:33:00 PM
From: j_fir2	Read Replies (1) \| Respond to of 10280

IJ, I know for a fact that that mechanism of action is not unique. It may be special, perhaps, in that it is powerful as an antidepressant. Effexor works on all three neurotransmitters, as does Wellbutrin (though very weakly for some of them). Also, this may be new news, recently revealed by research. But in the pharmaceutical world, no, they misspoke, I'm afraid. j'fir

To: IRWIN JAMES FRANKEL who wrote (3384)	6/29/1999 6:43:00 PM
From: j_fir2	Read Replies (1) \| Respond to of 10280

IJ, you quoted: "... studies indicate that (+)desmethylsibutramine may be a potent selective serotonin reuptake inhibitor (SSRI), norepinephrine and dopamine reuptake inhibitor. This UNIQUE triple mechanism of action may offer other benefits ..." I was referring to that quote when I said that they misspoke, because while special, say, that action is not unique to Meridia. I heard nothing contradictory at the meeting today, just information that I had not recalled knowing, and I couldn't find it referred to at SI, either, at least in the last three months. Wellbutrin is primarily a dopamine reuptake inhibitor, though as you say, it works weakly on the other two. I just thought I should include it when referencing other drugs that work on all three neurotransmitters. OK, hope that's clear. Best wishes, j'fir